65,437 trials
Pain · Quality of Life
Primary: Pain Score — 0.04; 0.14; 0.49; 0.40 units on a scale
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale Subscore D (Hyperarousal) — 25.59; 26.07; 21.20; 22.07 units on a scale — p=0.723
Glaucoma · Glaucoma, Open Angle
Primary: Proportion of Subjects Achieving a 20% or Greater Reduction in IOP From Baseline on the Same or Less Number of Medications — 46 Participants
Pancreatic Cancer
Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…
Cerebral Palsy · Muscle Spasticity · Children
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Reported in the Double Blind (DB) + Open Label (OL) Period. — 177; 5; 91; 151 participants
Oxygen Administration During Deep Sedation
Primary: Number of Participants With Oxygen Saturations Below 92% — 3; 12 Participants
Prostate Cancer
Primary: PSA Response Rate — 18 Participants
Sleep Initiation and Maintenance Disorders
Primary: Assessment of Clinical Global Impression-change. — 3.0; 4.2; 2.7 units on a scale
Primary Biliary Cirrhosis
Primary: Number of Participants With Adverse Events — 1; 3; 2 Participants
Legally Induced Abortion Without Mention of Complication
Primary: Procedure Time — 13; 12; 18.5 minutes
Diabetes Mellitus
Primary: Mean Daily Blood Glucose Levels During Hospital — 154.8; 156.0 mg/dL
Pain
Primary: Change From Baseline of Pain as Described by Numeric Rating Scale (NRS) [Minimum:0, Maximum 10] at 15 Minutes — 3.5; 6.0 units on a scale
Rhinovirus
Primary: Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire — -9.12; -5.11 Scores on a scale — p=0.020
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.3 percentage of participants